Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Constellation Brands

Constellation Brands Raises $45B in Public

207 High Point Drive, Victor, NY 14564January 1, 20242 min read
Employees
9000+

Constellation Brands Raises $45B in Public


Constellation Brands has successfully raised $45B in a Public at a $48B valuation led by Public.


Company Overview


Constellation Brands is a Beverages company headquartered in 207 High Point Drive, Victor, NY 14564, founded in 1945 with 9000+ employees.


Alcoholic beverage company


Fundraising Details


  • Amount Raised: $45B
  • Round Type: Public
  • Valuation: $48B
  • Date: 2024-01-01
  • Investors: Public

About Constellation Brands


Alcoholic beverage company The company is positioned in the Beverages sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 207 High Point Drive, Victor, NY 14564
  • Founded: 1945
  • Team Size: 9000+
  • Industry: Beverages

What This Means


This funding round demonstrates strong investor confidence in Constellation Brands's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Beverages sector continues to attract significant investment as companies innovate to meet evolving market demands. Constellation Brands's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $48B valuation marks an important milestone for Constellation Brands, positioning the company among notable players in the Beverages industry.


Looking Ahead


With this new capital, Constellation Brands is well-positioned to execute on its growth strategy and continue building innovative solutions in the Beverages space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-01-01. For more information about Constellation Brands, visit their headquarters at 207 High Point Drive, Victor, NY 14564.

Company Info

Headquarters
207 High Point Drive, Victor, NY 14564
Founded
1945
Team Size
9000+

Topics

Fundraising(2912)Public(771)BeveragesConstellation Brands

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free